Global Neurology Academy - Global Neurology Academy

Global Neurology Academy

Global Neurology Academy

Enhance your practice with CME
and tools that focus on the management
of neurological conditions.

Popular

FXIa Remix! Keeping the Flow Without Missing a Beat
FXIa Remix! Keeping the Flow Without Missing a Beat
CME/CE
FXIa Remix! Keeping the Flow Without Missing a Beat
Mike Sharma, MD, MSc, FRCPC; Ashkan Shoamanesh, MD
0.50 credits
- Mike Sharma, MD, MSc, FRCPC
- Ashkan Shoamanesh, MD
- Brian Mac Grory, MB, BCh BAO, MRCP, FAHA, FANA
0.50 credits
When “Mild” Matters Most: Closing Clinical Gaps in Early Symptomatic AD
When “Mild” Matters Most: Closing Clinical Gaps in Early Symptomatic AD
CME/CE Virtual Event
When “Mild” Matters Most: Closing Clinical Gaps in Early Symptomatic AD
June 03, 2026
06:00 PM - 07:00 PM CEST
1.00 credit
Understanding Variability in Myasthenia Gravis
Understanding Variability in Myasthenia Gravis
NeuroFrontiers
Understanding Variability in Myasthenia Gravis
Henry Kaminski, MD
- Henry Kaminski, MD
Emerging Focus in NAION: Sharpening Diagnostic Precision for Tomorrow’s Treatments
Emerging Focus in NAION: Sharpening Diagnostic Precision for Tomorrow’s Treatments
CME/CE Broadcast Replay
Emerging Focus in NAION: Sharpening Diagnostic Precision for Tomorrow’s Treatments
Prem S. Subramanian, MD, PhD; Andrew G. Lee, MD
1.00 credit
- Prem S. Subramanian, MD, PhD
- Andrew G. Lee, MD
- Valerie Biousse, MD
1.00 credit
Examining the Global Genetic Prevalence of TK2d
Examining the Global Genetic Prevalence of TK2d
NeuroFrontiers
Examining the Global Genetic Prevalence of TK2d
Brian P. McDonough, MD, FAAFP; Austin Larson, MD
- Brian P. McDonough, MD, FAAFP
- Austin Larson, MD
CME/CE In-Person & Virtual Event
Advancing Acromegaly Care: Diving Deeper Into Diagnosis, Guideline Application, and Emerging Therapies—A Fireside Chat With Expert Perspectives
June 15, 2026
Chicago, Illinois
1.50 credits
Tau Therapies and Clinical Translation: Mechanistic Approaches
Tau Therapies and Clinical Translation: Mechanistic Approaches
MinuteCE®
Tau Therapies and Clinical Translation: Mechanistic Approaches
Dani Cabral, MD; Mohammed Q. Al-Sabbagh, MD
0.75 program credits
- Dani Cabral, MD
- Mohammed Q. Al-Sabbagh, MD
0.75 program credits
Amyloid-β Therapies in Practice: Not All Are Created Equal
Amyloid-β Therapies in Practice: Not All Are Created Equal
MinuteCE®
Amyloid-β Therapies in Practice: Not All Are Created Equal
Dani Cabral, MD; Mohammed Q. Al-Sabbagh, MD
0.75 program credits
- Dani Cabral, MD
- Mohammed Q. Al-Sabbagh, MD
0.75 program credits

Medical News

Medical News
Intravenous Tirofiban After Tenecteplase in Acute Ischemic Stroke
05/11/2026
Read more
Medical News
Phenoconversion Risk in Pure Autonomic Failure
05/11/2026
Read more
Medical News
Inebilizumab vs Low-Dose Rituximab In NMOSD
05/05/2026
Read more
Medical News
Season Timing and Concussion Outcomes in Division I Football
05/04/2026
Read more

CME/CE

Rethinking Secondary Stroke Prevention: The Emerging Role of Factor XI Inhibition
Rethinking Secondary Stroke Prevention: The Emerging Role of Factor XI Inhibition
CME/CE
Rethinking Secondary Stroke Prevention: The Emerging Role of Factor XI Inhibition
Mukul Sharma, MD, MSc, FRCPC; Ashkan Shoamanesh, MD, MSc, FRCPC
0.75 credits
- Mukul Sharma, MD, MSc, FRCPC
- Ashkan Shoamanesh, MD, MSc, FRCPC
0.75 credits
Unseen Impact of NPS in AD: Domains and Burden
Unseen Impact of NPS in AD: Domains and Burden
MinuteCE®
Unseen Impact of NPS in AD: Domains and Burden
Dani Cabral, MD; Mohammed Q. Al-Sabbagh, MD
0.75 program credits
- Dani Cabral, MD
- Mohammed Q. Al-Sabbagh, MD
0.75 program credits
NPS Agitation: Evidence and Emerging Mechanisms of Management
NPS Agitation: Evidence and Emerging Mechanisms of Management
MinuteCE®
NPS Agitation: Evidence and Emerging Mechanisms of Management
Dani Cabral, MD; Mohammed Q. Al-Sabbagh, MD
0.75 program credits
- Dani Cabral, MD
- Mohammed Q. Al-Sabbagh, MD
0.75 program credits
CME/CE In-Person & Virtual Event
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
September 30, 2026
Orlando, Florida
1.00 credit

Clinical Practice

When “Mild” Matters Most: Closing Clinical Gaps in Early Symptomatic AD
When “Mild” Matters Most: Closing Clinical Gaps in Early Symptomatic AD
CME/CE Virtual Event
When “Mild” Matters Most: Closing Clinical Gaps in Early Symptomatic AD
June 17, 2026
06:00 PM - 07:00 PM CEST
1.00 credit
Microglia Drive Neurodegeneration in Friedreich’s Ataxia
Microglia Drive Neurodegeneration in Friedreich’s Ataxia
NeuroFrontiers
Microglia Drive Neurodegeneration in Friedreich’s Ataxia
Ryan Quigley
- Ryan Quigley
Is Friedreich’s Ataxia Developmental or Degenerative?
Is Friedreich’s Ataxia Developmental or Degenerative?
NeuroFrontiers
Is Friedreich’s Ataxia Developmental or Degenerative?
Arnulf Koeppen, MD
- Arnulf Koeppen, MD
SPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG
SPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG
NeuroFrontiers
SPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG

Programs

Identifying the Respiratory Manifestations of TK2d: The Pulmonologist’s Role
Identifying the Respiratory Manifestations of TK2d: The Pulmonologist’s Role
NeuroFrontiers
Identifying the Respiratory Manifestations of TK2d: The Pulmonologist’s Role
Charles Turck, PharmD, BCPS, BCCCP; Bethany Lussier, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Bethany Lussier, MD
MinuteCE®
Beyond Cognition: Managing Alzheimer’s as an Integrated Neurodegenerative–Neuropsychiatric Syndrome
Dani Cabral, MD; Marwan Sabbagh, MD, FAAN
0.75 credits 6 episodes
- Dani Cabral, MD
- Marwan Sabbagh, MD, FAAN
0.75 credits 6 episodes
Friedreich’s Ataxia: Impact of Frataxin Loss
Friedreich’s Ataxia: Impact of Frataxin Loss
NeuroFrontiers
Friedreich’s Ataxia: Impact of Frataxin Loss
Arnulf Koeppen, MD
- Arnulf Koeppen, MD
Advances in Cell-Based Therapy for MS
Advances in Cell-Based Therapy for MS
NeuroFrontiers
Advances in Cell-Based Therapy for MS
Mark Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC
- Mark Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC